Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Zinc Supplementation Improves Anticancer Activity of Monocytes in Type-2 Diabetic Patients with Metabolic Syndrome

KULWARA MEKSAWAN, URAIRAT SERMSRI and PITHI CHANVORACHOTE
Anticancer Research January 2014, 34 (1) 295-299;
KULWARA MEKSAWAN
1Department of Food and Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand
3Cell-based Drug and Health Product Development Research Unit, Chulalongkorn University, Bangkok, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
URAIRAT SERMSRI
1Department of Food and Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
PITHI CHANVORACHOTE
2Department of Physiology and Pharmacology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand
3Cell-based Drug and Health Product Development Research Unit, Chulalongkorn University, Bangkok, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: pithi_chan@yahoo.com
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Transmembrane tumor necrosis factor (TNF)-α, found on monocytes, is a body's key defense against cancer. In patients with type 2 diabetes mellitus (DM) and metabolic syndrome, immunity is suppressed, resulting in a high risk of several inflammatory disorders and cancer. Patients and Methods: Seventeen patients with type 2 DM and metabolic syndrome were supplemented with either 30 mg of elemental zinc/day or placebo for eight weeks. Transmembrane TNF-α-expressing monocytes and lymphocytes, and plasma TNF-α levels were analyzed before and after supplementation. Results: The present study revealed that zinc supplementation significantly increased the proportion of monocytes expressing transmembrane TNF-α. While the plasma TNF-α levels and TNF-α expressing lymphocytes were not significantly altered in the zinc-treated and placebo groups, higher proportion of TNF-α bound monocytes were observed in the zinc-treated group. Conclusion: Because functional transmembrane TNF-α was shown to be implicated in defense mechanisms, these findings suggest that zinc supplementation may benefit immune response against cancer in patients with DM and metabolic syndrome.

  • Metabolic syndrome
  • monocyte
  • transmembrane TNF-α
  • type 2 diabetes
  • zinc

It is well-documented that tumor necrosis factor (TNF)-α is an important pro-inflammatory cytokine playing a role in the pathogenesis of several inflammatory diseases (1). TNF-α is primarily produced by immune cells and adipocytes (2) like transmembrane TNF-α, which can be proteolytically cleaved by the TNF-α converting enzyme (TACE) to soluble TNF-α (3). In general, transmembrane TNF-α exerts biological functions through cell-to-cell contact and cell-type-specific manners, while the soluble form of TNF-α mediates its functions through less specific endocrine actions (4). Focusing on cancer, the function of transmembrane TNF-α in inhibition of cancer progression by eliminating cancer cells but preserving normal cells is accepted as being an important mechanism of the defense machinery against cancer (5, 6).

Importantly, in vivo evidence indicates that transmembrane TNF-α leads to death of cancer cells by a safer and more retainable antitumor activity than that of secreted TNF-α (7). Impaired mitogen-stimulated TNF-α production from immune cells in patients with diabetes mellitus (DM) has been proposed (8), and this alteration may be a possible mechanism for increased risk of cancer in these patients (9). A strategy which increases patients' functional transmembrane TNF-α would be beneficial in the attenuation of infections as well as the risk of cancer.

Metabolic syndrome is known to increase the risk of diabetes, and the presence of such metabolic abnormalities in patients with DM has been shown to lead to complications, especially cardiovascular disease and cancer (9, 10). It is interesting that an increased production of TNF-α by adipose tissue was frequently found in those with metabolic syndrome and DM (2); however, the body's overall defense function in such patients was poor (8, 11). Together with the evidence indicating that plasma TNF-α could render insulin resistance in patients with DM (12), and the membrane-bound form of TNF-α was shown to have a more potent role in eliminating an infection and unwanted cancer cells (7), investigations into the levels of transmembrane TNF-α and soluble TNF-α in patients with DM and metabolic syndrome would benefit a better understating of the roles of such a cytokine in pathology.

Several nutrients and natural substances have been shown to possess potential immunomodulating properties (13, 14). Among those, zinc, an essential trace mineral, which plays a vital role in growth and immune function, has garnered the most attention. Deficiency of zinc results in growth retardation, loss of appetite, and impaired immune function (15-18). Interestingly, zinc supplementation has been shown to reverse immune-related problems in many diseases (19, 20). A previous study revealed that the treatment of human peripheral blood mononuclear cells (PBMCs) with zinc resulted in an increased production of several immune-related cytokines, namely interleukin (IL)-6, IL-1β, and TNF-α (21). Moreover, an in vitro study showed that treatments of monocytes with zinc induced cytokine production in response to lipopolysaccharide (22).

The aforementioned information leads to the notion that zinc supplementation might benefit the immune function of patients with DM and metabolic syndrome. Therefore, the present study evaluated the effects of zinc supplementation on transmembrane TNF-α-expressing monocytes and lymphocytes and on circulating TNF-α levels in such patients.

Patients and Methods

Patients. Outpatients with type 2 DM and metabolic syndrome were recruited from the Public Health Center 66, Health Department, Bangkok Metropolitan. Metabolic syndrome was defined based on the International Diabetes Federation criteria (23). The 17 patients who agreed to participate in the study gave their written informed consent after they received information about the experimental procedures. This study was approved by the Ethics Committee for Researches involving Human Subjects, Bangkok Metropolitan Administration (Registered Number: 041.54).

Study design. This study was a randomized, placebo-controlled trial. The patients were randomly assigned into either the experimental group or the placebo group. The patients in the zinc-treated group were supplemented with zinc sulfate (one capsule containing 66 mg zinc sulfate equivalent to 15 mg elemental zinc), while the patients in the placebo group received placebo (66 mg corn starch). The patients in both groups were assigned to take two capsules of the supplement daily for eight weeks. At the beginning and the end of the study, blood samples were collected for analysis of transmembrane TNF-α on monocytes and lymphocytes and of plasma TNF-α level.

Isolation of PBMCs. Blood samples were drawn from antecubital vein, and PBMCs were isolated by Histopaque density gradient (Histopaque 1077; Sigma-Aldrich, St. Louis, MO, USA). The isolated PBMCs (1×106/ml) were finally resuspended in 1 ml of 1% bovine serum albumin in phosphate-buffered saline (PBS) and fixed with 4% paraformaldehyde for 10 min. After washing with PBS, the cells were incubated with fluorescein-conjugated monoclonal antibody against TNF-α (Sigma-Aldrich, St. Louis, MO, USA) and phycoerythrin-conjugated monoclonal antibody to cluster of differentiation 14 (CD14) (Sigma-Aldrich, St. Louis, MO, USA) for an analysis of transmembrane TNF-α on monocytes by flow cytometry.

Biochemical analysis. Blood samples were collected at baseline and after eight weeks of zinc/placebo supplementation to determine complete blood count and plasma levels of zinc, fasting blood glucose and glycated hemoglobin (HbA1c). Plasma TNF-α level was also analyzed by sandwich enzyme-linked immunosorbent assay (ELISA) using human TNF-α Quantikine® HS ELISA kit (R&D systems, Minneapolis, MN, USA). The mean minimum detectable dose according to the manufacturer protocol was 0.106 pg/ml.

Statistical analysis. The data are presented as the mean±standard deviation (SD). An independent sample t-test was used for a statistical comparison of data between the zinc-treated group and the placebo group. The comparisons of the data within each group were made using paired sample t-test. Statistical significance was considered for those with a p-value less than 0.05.

Results

The characteristics of the patients are presented in Table I. At baseline, our results indicated no significant differences in patients' characteristics, including plasma zinc and TNF-α levels, between the placebo and the zinc-treated groups.

Blood cell and plasma TNF-α levels. In order to investigate the effect of zinc supplementation on immune cells after zinc/placebo supplementation for eight weeks, the number of monocytes and lymphocytes, and the levels of plasma TNF-α were determined. Even though our results indicate that the level of plasma zinc in the zinc-treated group were significantly increased from baseline (p<0.05), and such levels were significantly higher than those in the placebo group (p<0.05), no significant alteration was found in terms of the number of monocytes and lymphocytes after 8-week zinc supplementation (Table II). In addition, the results revealed that no significant change in plasma TNF-α levels in either the placebo or zinc groups, in comparison to the corresponding baseline took place.

Expression of transmembrane TNF-α on monocytes and lymphocytes. Figure 1 shows the percentages of transmembrane TNF-α-expressing monocytes and lymphocytes. The results indicate that transmembrane TNF-α-expressing monocytes and lymphocytes at baseline were not different between placebo and zinc-treated groups. Interestingly, after 8-week zinc supplementation, the percentage of transmembrane TNF-α-expressing monocytes of patients in the zinc-treated group significantly increased from that at baseline (p<0.05), while no change of those in the patients of the placebo group was observed. In addition, the percentage of transmembrane TNF-α-expressing monocytes, week 8, of patients in the zinc-treated group was significantly higher than their placebo counterpart (p<0.05). However, zinc supplementation caused no significant effect on the percentage of transmembrane TNF-α-expressing lymphocytes of the patients in either group after eight weeks of study.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Characteristics of the patients at baseline.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

The effects of zinc supplementation on plasma zinc levels, the number of monocytes and lymphocytes and plasma tumor necrosis factor (TNF)-α levels.

Discussion

This study aimed to investigate the possible role of zinc supplementation in modulating immune functions of patients with DM and metabolic syndrome by characterizing the effects of such a supplementation on transmembrane TNF-α produced by PBMCs and on circulating TNF-α. Notably, the baseline plasma zinc levels of the patients in this study were found to be low compared to those in healthy individuals (24, 25). Abnormal zinc homeostasis in diabetic patients could be explained by impaired absorption or high urinary excretion (26). Deprived zinc status was associated with diabetic complications (27). Maintaining plasma zinc levels within the normal range could be accomplished with zinc supplementation and may be beneficial in optimizing zinc function and thus preventing complications in these patients. This study found that 8-week zinc supplementation resulted in improved plasma zinc levels in type-II diabetic patients with metabolic syndrome.

It is well-accepted that circulating TNF-α is associated with impaired glucose tolerance and increased insulin resistance (12), while transmembrane TNF-α was shown to be implicated in defense response against infections and cancer (7). In fact, monocytes and macrophages exhibit cytotoxic activity against tumor cells by the production of several toxic molecules, including reactive oxygen species (ROS), reactive nitrogen species, and TNF-α (7, 28). TNF-α, especially the transmembrane form has been shown to have a dominant impact on the inhibition of cancer progression (7). Our data indicate that administration of zinc at a dose of 30 mg/day for eight weeks resulted in the increase of transmembrane TNF-α but had no effect on circulating TNF-α, implying that such supplementation could have a positive effect on patient health with a lesser effect on insulin-resistant status.

DM is a group of common metabolic disorders resulting in high levels of glucose in the blood. Many factors contribute to hyperglycemia, including reduced insulin secretion, decreased glucose utilization, and increased glucose production. With metabolic syndrome, patients with type 2 DM were demonstrated to be at higher risk for complications such as cardiovascular disease compared to individuals without type 2 DM and metabolic syndrome (29). The role of transmembrane TNF-α in diabetes and metabolic syndrome is largely unknown but is currently receiving great attention. It is generally known that the impaired immune function often found in patients with DM leads to increased infections and a higher incidence of cancer (30). In case of infection, causes seem to be multi-factorial and complicated. One accepted explanation is that in DM patients this is due to defects of TNF-α expression from monocytes (30). A previous study reported an impaired activity in response to toll-like receptor (TLR) ligands and decreased phagocytotic activity in monocytes of type 2 diabetic patients (30). Decrease of monocyte-derived soluble TNF-α in response to stress, and abnormal PBMC function were demonstrated in patients with DM (11, 31). Consistent with the previous finding, our results support the role of zinc in enhanced TNF-α production in immune cells and further showed that monocytes are the most affected immune cells in such a case.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

The expression of transmembrane TNF-α on monocytes (A) and lymphocytes (B). *Significant difference at p<0.05.

In conclusion, our study has provided evidence, as far as we are aware for the first time, that zinc supplementation in patients with DM and metabolic syndrome may be beneficial since it significantly enhances transmembrane TNF-α expression on monocytes while having only a minimal effect on lymphocytes and the circulating level of TNF-α. These data may support the use of zinc in patients with DM.

Acknowledgements

This work was conducted under the Cell-based Drug and Health Products Development Research Unit, Chulalongkorn University. We thank Mr. Krich Rajprasit, a proofreader and Ms. Phattrakorn Powan. The laboratory instruments used in this research were partly supported by the Pharmaceutical Research Instrument Center and the Chulalongkorn University Centenary Academic Development Project, Faculty of Pharmaceutical Sciences, Chulalongkorn University.

  • Received November 21, 2013.
  • Revision received December 9, 2013.
  • Accepted December 10, 2013.
  • Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Bradley JR
    : TNF-mediated inflammatory disease. J Pathol 214: 149-160, 2008.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Xu H,
    2. Uysal KT,
    3. Becherer JD,
    4. Arner P,
    5. Hotamisligil GS
    : Altered tumor necrosis factor-α (TNF-α) processing in adipocytes and increased expression of transmembrane TNF-α in obesity. Diabetes 51: 1876-1883, 2002.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Black RA,
    2. Rauch CT,
    3. Kozlosky CJ,
    4. Peschon JJ,
    5. Slack JL,
    6. Wolfson MF,
    7. Castner BJ,
    8. Stocking KL,
    9. Reddy P,
    10. Srinivasan S,
    11. Nelson N,
    12. Boiani N,
    13. Schooley KA,
    14. Gerhart M,
    15. Davis R,
    16. Fitzner JN,
    17. Johnson RS,
    18. Paxton RJ,
    19. March CJ,
    20. Cerretti DP
    : A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385: 729-733, 1997.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Horiuchi T,
    2. Mitoma H,
    3. Harashima S,
    4. Tsukamoto H,
    5. Shimoda T
    : Transmembrane TNF-α: Structure, function and interaction with anti-TNF agents. Rheumatology 49: 1215-1228, 2010.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Van Horssen R,
    2. Ten Hagen TL,
    3. Errgermont AM
    : TNF-α in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 11: 397-408, 2006.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Calzascia T,
    2. Pellegrini M,
    3. Hall H,
    4. Sabbagh L,
    5. Ono N,
    6. Elford AR,
    7. Mak TW,
    8. Ohashi PS
    : TNF-α is critical for antitumor but not antiviral T cell immunity in mice. J Clin Invest 117(12): 3833-3845, 2007.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Li Q,
    2. Li L,
    3. Shi W,
    4. Jiang X,
    5. Xu Y,
    6. Gong F,
    7. Zhou M,
    8. Edwards CK III.,
    9. Li Z
    : Mechanism of action differences in the antitumor effects of transmembrane and secretory tumor necrosis factor-alpha in vitro and in vivo. Cancer Immunol Immunother 55: 1470-1479, 2006.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Zykova SN,
    2. Svartberg J,
    3. Seljelid R,
    4. Iversen H,
    5. Lund A,
    6. Svistounov DN,
    7. Jenssen TG
    : Release of TNF-alpha from in vitro-stimulated monocytes is negatively associated with serum levels of apolipoprotein B in patients with type 2 diabetes. Scand J Immunol 60: 535-542, 2004.
    OpenUrlPubMed
  9. ↵
    1. Braun S,
    2. Bitton-Worms K,
    3. LeRoith D
    : The link between the metabolic syndrome and cancer. Inter J Biol Sci 7(7): 1003-1015, 2011.
    OpenUrl
  10. ↵
    1. Grundy SM,
    2. Brewer HB Jr..,
    3. Cleeman JI,
    4. Smith SC Jr..,
    5. Lenfant C,
    6. American Heart Association,
    7. National Heart, Lung, and Blood Institute
    : Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109: 433-438, 2004.
    OpenUrlFREE Full Text
  11. ↵
    1. Geerlings SE,
    2. Brouwer EC,
    3. Van Kessel KC,
    4. Gaastra W,
    5. Stolk RP,
    6. Hoepelman AI
    : Cytokine secretion is impaired in women with diabetes mellitus. Eur J Clin Invest 30: 995-1001, 2000.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Miyazaki Y,
    2. Pipek R,
    3. Mandarino LJ,
    4. DeFronzo RA
    : Tumor necrosis factor α and insulin resistance in obese type 2 diabetic patients. Int J Obes Relat Metab Disord 27: 88-94, 2003.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Grimble RF
    : Nutritional modulation of immune function. Proc Nutr Soc 60: 389-397, 2001.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Maggini S,
    2. Wintergerst ES,
    3. Beveridge S,
    4. Hornig DH
    : Selected vitamins and trace elements support immune function by strengthening epithelial barriers and cellular and humoral immune responses. Br J Nutr 98(Suppl 1): S29-S35, 2007.
    OpenUrlPubMed
  15. ↵
    1. Shay NF,
    2. Mangian HF
    : Neurobiology of zinc-influenced eating behavior. J Nutr 130(5S Suppl): 1493S-1499S, 2000.
    OpenUrlAbstract/FREE Full Text
    1. Umeta M,
    2. West CE,
    3. Haidar J,
    4. Deurenberg P,
    5. Hautvast JG
    : Zinc supplementation and stunted infants in Ethiopia: a randomised controlled trial. Lancet 355: 2021-2026, 2000.
    OpenUrlCrossRefPubMed
    1. Bao B,
    2. Prasad AS,
    3. Beck FW,
    4. Godmere M
    : Zinc modulates mRNA levels of cytokines. Am J Physiol Endocrinol Metab 285: E1095-E1102, 2003.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Cole CR,
    2. Lifshitz F
    : Zinc nutrition and growth retardation. Pediatr Endocrinol Rev 5: 889-896, 2008.
    OpenUrlPubMed
  17. ↵
    1. Bao B,
    2. Prasad AS,
    3. Beck FWJ,
    4. Snell D,
    5. Suneja A,
    6. Sarkar FH,
    7. Doshi N,
    8. Fitzgerald JT,
    9. Swerdlow P
    : Zinc supplementation decreases oxidative stress, incidence of infection, and generation of inflammatory cytokines in sickle cell disease patients. Transl Res 152: 67-80, 2008.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Baum MK,
    2. Lai S,
    3. Sales S,
    4. Page JB,
    5. Campa A
    : Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV-infected adults. Clin Infect Dis 50(12): 1653-1660, 2010.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Ibs KH,
    2. Rink L
    : Zinc-altered immune function. J Nutr 133: 1452S-1456S, 2003.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Haase H,
    2. Ober-Blobaum JL,
    3. Engelhardt G,
    4. Hebel S,
    5. Heit A,
    6. Heine H,
    7. Rink L
    : Zinc signals are essential for lipopolysaccharide-induced signal transduction in monocytes. J Immunol 181: 6491-6502, 2008.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Alberti KG,
    2. Zimmet P,
    3. Shaw J
    : IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet 366: 1059-1062, 2005.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Brown KH
    : Effect of infections on plasma zinc concentration and implications for zinc status assessment in low-income countries. Am J Clin Nutr 68(suppl): 425S-429S, 1998.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Al-Maroof RA,
    2. Al-Sharbatti SS
    : Serum zinc levels in diabetic patients and effect of zinc supplementation on glycemic control of type 2 diabetics. Saudi Med J 27(3): 344-350, 2006.
    OpenUrlPubMed
  24. ↵
    1. Chausmer AB
    : Zinc, insulin and diabetes. J Am Coll Nutr 17: 109-115, 1998.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Soinio M,
    2. Marniemi J,
    3. Laakso M,
    4. Pyörälä K,
    5. Lehto S,
    6. Rönnemaa T
    : Serum zinc level and coronary heart disease events in patients with type 2 diabetes. Diabetes Care 30: 523-528, 2007.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Martin JH,
    2. Edwards SW
    : Changes in mechanisms of monocyte/macrophage-mediated cytotoxicity during culture. Reactive oxygen intermediates are involved in monocyte-mediated cytotoxicity, whereas reactive nitrogen intermediates are employed by macrophages in tumor cell killing. J Immunol 150: 3478-3486, 1993.
    OpenUrlAbstract
  27. ↵
    1. Haffner SM
    : Risk constellations in patients with the metabolic syndrome: epidemiology, diagnosis, and treatment patterns. Am J Med 119(5 Suppl 1): S3-S9, 2006.
    OpenUrlPubMed
  28. ↵
    1. Komura T,
    2. Sakai Y,
    3. Honda M,
    4. Takamura T,
    5. Matsushima K,
    6. Kaneko S
    : CD14+ monocytes are vulnerable and functionally impaired under endoplasmic reticulum stress in patients with type 2 diabetes. Diabetes 59(3): 634-643, 2010.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Alexandraki KI,
    2. Piperi C,
    3. Ziakas PD,
    4. Apostolopoulos NV,
    5. Makrilakis K,
    6. Syriou V,
    7. Diamanti-Kandarakis E,
    8. Kaltsas G,
    9. Kalofoutis A
    : Cytokine secretion in long-standing diabetes mellitus type 1 and 2: Associations with low-grade systemic inflammation. J Clin Immunol 28(4): 314-321, 2008.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 34 (1)
Anticancer Research
Vol. 34, Issue 1
January 2014
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Zinc Supplementation Improves Anticancer Activity of Monocytes in Type-2 Diabetic Patients with Metabolic Syndrome
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Zinc Supplementation Improves Anticancer Activity of Monocytes in Type-2 Diabetic Patients with Metabolic Syndrome
KULWARA MEKSAWAN, URAIRAT SERMSRI, PITHI CHANVORACHOTE
Anticancer Research Jan 2014, 34 (1) 295-299;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Zinc Supplementation Improves Anticancer Activity of Monocytes in Type-2 Diabetic Patients with Metabolic Syndrome
KULWARA MEKSAWAN, URAIRAT SERMSRI, PITHI CHANVORACHOTE
Anticancer Research Jan 2014, 34 (1) 295-299;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Acknowledgements
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Triage Process at Endoscopy With ColonView Fecal Immunochemical Test (FIT) Will Enhance Diagnostic Accuracy (DA) of Colorectal Cancer Screening
  • Laparoscopic Colorectal Cancer Surgery for Patients With Severe Chronic Heart Failure
  • Clinical Impact of Prehabilitation on Elective Laparoscopic Surgery in Frail Octogenarians With Colorectal Cancer
Show more Clinical Studies

Similar Articles

Keywords

  • metabolic syndrome
  • monocyte
  • transmembrane TNF-α
  • type 2 diabetes
  • Zinc
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire